Recombinant human erythropoietin stimulates melanoma tumor growth through activation of initiation factor eIF4E

Recombinant human erythropoietin (EPO) is standard treatment for anemia in cancer patients. Recent clinical trials suggest that EPO may accelerate tumor progression and increase mortality. However, the evidence supporting a growth-promoting effect of EPO has remained controversial. Employing an in v...

Descripción completa

Detalles Bibliográficos
Autores principales: Julius, Annabelle, Desai, Anjali, Yung, Raymond L.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Impact Journals LLC 2017
Materias:
Research Paper
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5444745/
https://www.ncbi.nlm.nih.gov/pubmed/28415825
http://dx.doi.org/10.18632/oncotarget.16331

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5444745/
https://www.ncbi.nlm.nih.gov/pubmed/28415825
http://dx.doi.org/10.18632/oncotarget.16331

Ejemplares similares